Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer

doi:10.1053/j.gastro.2019.06.048

Gastroenterology

Volume 158, Issue 2, January 2020, Pages 322-340

https://doi.org/10.1053/j.gastro.2019.06.048 Get rights and content

Researchers have discovered associations between elements of the intestinal microbiome (including specific microbes, signaling pathways, and microbiota-related metabolites) and risk of colorectal cancer (CRC). However, it is unclear whether changes in the intestinal microbiome contribute to the development of sporadic CRC or result from it. Changes in the intestinal microbiome can mediate or modify the effects of environmental factors on risk of CRC. Factors that affect risk of CRC also affect the intestinal microbiome, including overweight and obesity; physical activity; and dietary intake of fiber, whole grains, and red and processed meat. These factors alter microbiome structure and function, along with the metabolic and immune pathways that mediate CRC development. We review epidemiologic and laboratory evidence for the influence of the microbiome, diet, and environmental factors on CRC incidence and outcomes. Based on these data, features of the intestinal microbiome might be used for CRC screening and modified for chemoprevention and treatment. Integrated prospective studies are urgently needed to investigate these strategies.

Section snippets

Intestinal Dysbiosis in Patients With Colorectal Cancer

The number of microbial species in human intestine is estimated to exceed 2000.¹³ The human intestinal microbiome primarily comprises Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. Intestinal microbes metabolize indigestible ingredients from food, synthesize nutrients such as vitamins, detoxify metabotypes, modulate the immune response, provide signals for epithelial cell renewal and maintenance of mucosal integrity, and secrete antimicrobial products.¹⁴ Dysbiosis is defined as

Environmental Factors

The composition of microbiota is determined by genetic, environmental, and dietary factors. For example, variants in the gene encoding the vitamin D receptor affect the composition of the microbiome,⁷⁶ but it is still not clear whether genetic or environmental factors have a bigger effect on the gut microbiome.⁷⁷ Although there is no direct evidence, CRC-related risk factors have been associated with specific changes in the intestinal microbiota.

Mechanisms

The intestine must maintain commensal microbes and a high load of bacterial products but swiftly respond to pathogens that threaten its integrity. Analyses of gut microbiota of mice raised in germ-free or gnotobiotic conditions and transgenic mice, by using techniques such as next-generation sequencing, microbial gene mutations, and microbial RNA sequencing, have identified mechanisms by which the intestinal microbiota might contribute to or prevent the development of CRC (Figure 1). For

Screening

Alterations in the fecal microbiomes of patients with CRC have also been observed in patients with colorectal adenoma—these might be used in screening for individuals at risk for CRC. Fecal microbiome analysis identifies patients with adenomas with reasonable levels of accuracy (with area under the receiver operating curves ranging from 0.55 to 0.67 in validation studies), although this is a lower value than for detection of CRC.¹⁶^,¹⁸^,186, 187, 188 Combining the fecal microbiome data with

Therapy

In addition to affecting CRC development, the gut microbiota modulates the response to cancer therapy and susceptibility to toxic adverse effects, although there is only limited evidence from patients (for reviews, see Roy and Trinchieri⁸ and Alexander et al¹⁸⁹). In 2013, Iida et al¹⁹⁰ reported that alterations in the intestinal microbiota can affect the efficacy of an immunotherapy (CpG-oligonucleotide) and oxaliplatin, a platinum compound used in chemotherapy for CRC and other cancers. Both

Future Directions

Epidemiologic evidence for the effects of the gut microbiome on CRC risk comes from retrospective case-control studies of biospecimens collected from patients with established CRC or precursor lesions. It is not clear whether the identified microbial alterations are a cause or consequence of colorectal carcinogenesis.²⁰⁹ Moreover, clinical studies have been limited by small sample sizes (mostly <100 cases), likely underpowered to identify predictive signals from hundreds to thousands of read

References (224)

M. Song et al.
Environmental factors, gut microbiota, and colorectal cancer prevention
Clin Gastroenterol Hepatol
(2019)
H. Tilg et al.
The intestinal microbiota in colorectal cancer
Cancer Cell
(2018)
J. Sun et al.
Exploring gut microbes in human health and disease: pushing the envelope
Genes Dis
(2014)
A. Swidsinski et al.
Association between intraepithelial Escherichia coli and colorectal cancer
Gastroenterology
(1998)
H.M. Martin et al.
Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer
Gastroenterology
(2004)
J. Sun et al.
Gut microbiota, inflammation and colorectal cancer
Genes Dis
(2016)
A. Koh et al.
From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites
Cell
(2016)
S. Shoaie et al.
Quantifying diet-induced metabolic changes of the human gut microbiome
Cell Metab
(2015)
R.L. Siegel et al.
Cancer statistics, 2019
CA Cancer J Clin
(2019)
R.L. Siegel et al.
Colorectal cancer statistics, 2017
CA Cancer J Clin
(2017)

M. Song et al.

Nutrients, foods, and colorectal cancer prevention

Gastroenterology

(2015)

F. Islami et al.

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States

CA Cancer J Clin

(2018)

K. Mima et al.

Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location

Clin Transl Gastroenterol

(2016)

A.J. Scott et al.

International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis

Gut

(2019)

S. Roy et al.

Microbiota: a key orchestrator of cancer therapy

Nat Rev Cancer

(2017)

Z. Dai et al.

The role of microbiota in the development of colorectal cancer

Int J Cancer

(2019)

T.O. Keku et al.

The gastrointestinal microbiota and colorectal cancer

Am J Physiol Gastrointest Liver Physiol

(2015)

Y. Yang et al.

Novel insights into microbiome in colitis and colorectal cancer

Curr Opin Gastroenterol

(2017)

A. Almeida et al.

A new genomic blueprint of the human gut microbiota

Nature

(2019)

J. Ahn et al.

Human gut microbiome and risk for colorectal cancer

J Natl Cancer Inst

(2013)

A.M. Thomas et al.

Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation

Nat Med

(2019)

M.A. Sze et al.

Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors

MBio

(2018)

Q. Feng et al.

Gut microbiome development along the colorectal adenoma-carcinoma sequence

Nat Commun

(2015)

G. Nakatsu et al.

Gut mucosal microbiome across stages of colorectal carcinogenesis

Nat Commun

(2015)

S. Yachida et al.

Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer

Nat Med

(2019)

M. Castellarin et al.

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma

Genome Res

(2012)

A.D. Kostic et al.

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

Genome Res

(2012)

L. Flanagan et al.

Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome

Eur J Clin Microbiol Infect Dis

(2014)

M. Ito et al.

Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway

Int J Cancer

(2015)

Y.Y. Li et al.

Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients

World J Gastroenterol

(2016)

K. Mima et al.

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis

Gut

(2016)

T. Tahara et al.

Fusobacterium in colonic flora and molecular features of colorectal carcinoma

Cancer Res

(2014)

T. Yu et al.

Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy

Cell

(2017)

K. Nosho et al.

Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer

World J Gastroenterol

(2016)

K. Mima et al.

Fusobacterium nucleatum and T cells in colorectal carcinoma

JAMA Oncol

(2015)

S. Rashtak et al.

Sessile serrated polyps and colon cancer prevention

Cancer Prev Res (Phila)

(2017)

R.V. Purcell et al.

Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer

Sci Rep

(2017)

J. Guinney et al.

The consensus molecular subtypes of colorectal cancer

Nat Med

(2015)

S. Bullman et al.

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

Science

(2017)

J.P. Zackular et al.

The human gut microbiome as a screening tool for colorectal cancer

Cancer Prev Res (Phila)

(2014)

G. Zeller et al.

Potential of fecal microbiota for early-stage detection of colorectal cancer

Mol Syst Biol

(2014)

E. Vogtmann et al.

Colorectal cancer and the human gut microbiome: reproducibility with whole-genome shotgun sequencing

PLoS One

(2016)

F. Momen-Heravi et al.

Periodontal disease, tooth loss and colorectal cancer risk: results from the Nurses’ Health Study

Int J Cancer

(2017)

Q. Liang et al.

Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer

Clin Cancer Res

(2017)

A. Boleij et al.

The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients

Clin Infect Dis

(2015)

R.V. Purcell et al.

Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia

PLoS One

(2017)

C.M. Dejea et al.

Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria

Science

(2018)

K.S. Viljoen et al.

Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer

PLoS One

(2015)

N.U. Toprak et al.

A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer

Clin Microbiol Infect

(2006)

T. Wang et al.

Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers

ISME J

(2012)

Cited by (405)

Xianlian Jiedu Decoction alleviates colorectal cancer by regulating metabolic profiles, intestinal microbiota and metabolites
2024, Phytomedicine
Xianlian Jiedu Decoction (XLJDD) has been used for the treatment of colorectal cancer (CRC) for several decades because of the prominent efficacy of the prescription. Despite the clear clinical efficacy of XLJDD, the anti-CRC mechanism of action is still unclear.
The inhibitory effect and mechanism of XLJDD on CRC were investigated in the azoxymethane/dextran sulfate sodium (AOM/DSS)-induced mice.
The AOM/DSS-induced mice model was adopted to evaluate the efficacy after administering the different doses of XLJDD. The therapeutic effects of XLJDD in treating AOM/DSS-induced CRC were investigated through histopathology, immunofluorescence and ELISA analysis methods. In addition, metabolomics profile and 16S rRNA analysis were used to explore the effective mechanisms of XLJDD on CRC.
The results stated that the XLJDD reduced the number of tumor growth on the inner wall of the colon and the colorectal weight/length ratio, and suppressed the disease activity index (DAI) score, meanwhile XLJDD also increased body weight, colorectal length, and overall survival rate. The treatment of XLJDD also exhibited the ability to lower the level of inflammatory cytokines in serum and reduce the expression levels of β-catenin, COX-2, and iNOS protein in colorectal tissue. The findings suggested that XLJDD has anti-inflammatory properties and may provide relief for those suffering from inflammation-related conditions. Mechanistically, XLJDD improved gut microbiota dysbiosis and associated metabolic levels of short chain fatty acids (SCFAs), sphingolipid, and glycerophospholipid. This was achieved by reducing the abundance of Turicibacter, Clostridium_sensu_stricto_1, and the levels of sphinganine, LPCs, and PCs. Additionally, XLJDD increased the abundance of Enterorhabdus and Alistipes probiotics, as well as the content of butyric acid and isovaleric acid.
The data presented in this article demonstrated that XLJDD can effectively inhibit the occurrence of colon inner wall tumors by reducing the level of inflammation and alleviating intestinal microbial flora imbalance and metabolic disorders. It provides a scientific basis for clinical prevention and treatment of CRC.
Anchang Yuyang Decoction inhibits experimental colitis-related carcinogenesis by regulating PPAR signaling pathway and affecting metabolic homeostasis of host and microbiota
2024, Journal of Ethnopharmacology
Inflammatory bowel disease (IBD) presents a risk of carcinogenesis, which escalates with the duration of IBD. Persistent histological inflammation is considered to be the driving factor of colitis carcinogenesis. Effective control of inflammation is helpful to prevent and treat colitis-related colorectal cancer (CAC). Anchang Yuyang Decoction (AYD), a traditional Chinese medicine (TCM) formula, is originated from the ancient prescription of TCM for treating colitis and colorectal cancer. AYD has demonstrated efficacy in treating IBD and potential anti-carcinogenic properties.
This research aims to assess the therapeutic efficacy of AYD in ameliorating experimental colitis-related carcinogenesis induced by AOM/DSS. It further seeks to elucidate its potential mechanisms by integrating multiple omics sequencing approaches.
A rat model for colitis-related carcinogenesis was developed using azoxymethane (AOM)/dextran sulfate sodium (DSS). UPLC-MS identified AYD's chemical constituents. Rats were administered varying doses of AYD (18.37, 9.19 and 4.59 g/kg) orally for 53 days, with mesalazine as a positive control. The study evaluated anti-carcinogenic effects by examining adenoma number, adenoma load, abnormal crypt foci (ACF), histopathological damage, and tumor-related protein expression. Anti-inflammatory and reparative effects were assessed through body weight, disease activity index (DAI), colon length, spleen index, inflammatory cytokine levels, and tight junction protein expression. The effects on intestinal microbiota and host metabolism were explored through 16S rRNA sequencing, targeted short-chain fatty acid (SCFA) metabonomics, and non-targeted colon metabolomics. Potential AYD targets were identified through transcriptomic sequencing and validated by qRT-PCR and western blotting.
AYD significantly reduced adenoma number, adenoma load, neoplasm-associated lesions, ACF, and tumor-related protein expression (e.g., p53, PCNA) in AOM/DSS-induced rats, thus impeding colitis-related carcinogenesis progression. AYD also alleviated histopathological damage and inflammation, promoting intestinal mucosal barrier repair. Furthermore, AYD modulated intestinal flora structure, enhanced SCFA production, and regulated colon metabolites. Transcriptomic sequencing revealed a significant impact on the peroxisome proliferator-activated receptor (PPAR) signaling pathway. Subsequent qRT-PCR and western blotting experiments indicated AYD's influence in up-regulating PPAR-γ and down-regulating PPAR-α, PPAR-β/δ, and related proteins (thrombomodulin [Thbd], fatty acid binding protein 5 [Fabp5], stearoyl-CoA desaturase 2 [Scd2], phospholipid transfer protein [Pltp]).
This study demonstrates AYD's ability to inhibit experimental colitis-related carcinogenesis induced by AOM/DSS. Its mechanism likely involves modulation of the PPAR signaling pathway, impacting intestinal microbiota and host metabolic equilibrium.
Exploring the gut microbiota and its potential as a biomarker in gliomas
2024, Biomedicine and Pharmacotherapy
Gut microbiome alterations are associated with various cancers including brain tumours such as glioma and glioblastoma. The gut communicates with the brain via a bidirectional pathway known as the gut-brain axis (GBA) which is essential for maintaining homeostasis. The gut microbiota produces many metabolites including short chain fatty acids (SCFAs) and essential amino acids such as glutamate, glutamine, arginine and tryptophan. Through the modulation of these metabolites the gut microbiome is able to regulate several functions of brain cells, immune cells and tumour cells including DNA methylation, mitochondrial function, the aryl hydrocarbon receptor (AhR), T-cell proliferation, autophagy and even apoptosis. Here, we summarise current findings on gut microbiome with respect to brain cancers, an area of research that is widely overlooked. Several studies investigated the relationship between gut microbiota and brain tumours. However, it remains unclear whether the gut microbiome variation is a cause or product of cancer. Subsequently, a biomarker panel was constructed for use as a predictive, prognostic and diagnostic tool with respect to multiple cancers including glioma and glioblastoma multiforme (GBM). This review further presents the intratumoural microbiome, a fascinating microenvironment within the tumour as a possible treatment target that can be manipulated to maximise effectiveness of treatment via personalised therapy. Studies utilising the microbiome as a biomarker and therapeutic strategy are necessary to accurately assess the effectiveness of the gut microbiome as a clinical tool with respect to brain cancers.
Effect size of delayed freezing, diurnal variation, and hindgut location on the mouse fecal microbiome
2024, iScience
Practical considerations in fecal sample collection for microbiome research include time to sample storage, time of collection, and hindgut position during terminal collections. Here, parallel experiments were performed to investigate the relative effect of these factors on microbiome composition in mice colonized with two different vendor-origin microbiomes. 16S rRNA amplicon sequencing of immediately flash-frozen feces showed no difference in alpha or beta diversity compared to samples incubated up to 9 h at room temperature. Samples collected in the morning showed greater alpha diversity compared to samples collected in the afternoon. While a significant effect of time was detected in all hindgut regions, the effect increased from cecum to distal colon. This study highlights common scenarios in microbiome research that may affect outcome measures of microbial community analysis. However, we demonstrate a relatively low effect size of these technical factors when compared to a primary experimental factor with large intergroup variability.
Cardiovascular-specific mortality and risk factors in colorectal Cancer patients: A cohort study based on registry data of over 500,000 individuals in the US
2024, Preventive Medicine
Colorectal cancer (CRC) is one of the most common cancers worldwide, and recent studies have found that CRC patients are at increased risk for cardiovascular disease (CVD). This study aimed to investigate competing causes of death and prognostic factors among a large cohort of CRC patients and to describe cardiovascular-specific mortality in relation to the US standard population.
This registry-based cohort study identified patients diagnosed with CRC between 1973 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database in the US. Cumulative mortality functions, conditional standardized mortality ratios, and cause-specific hazard ratios were calculated.
Of the 563,298 eligible CRC patients included in this study, 407,545 died during the follow-up period. CRC was the leading cause of death, accounting for 49.8% of all possible competing causes of death. CVD was the most common non-cancer cause of death, accounting for 17.8% of total mortality. This study found that CRC patients have a significantly increased risk of cardiovascular-specific mortality compared to the US standard population, with the risk increasing with age and extended survival time.
This study highlights the need to develop multidisciplinary prevention and management strategies for CRC and CVD to improve CRC patients' survival and quality of life.
Healthy dietary patterns, genetic risk, and gastrointestinal cancer incident risk: a large-scale prospective cohort study
2024, American Journal of Clinical Nutrition
Dietary patterns have been associated with several cancers, especially gastrointestinal cancer (GIC). However, whether a healthy dietary pattern could modify the risk of GIC among people with different genetic backgrounds is not clear.
The objective of the study was to investigate how dietary patterns and genetic susceptibility contribute to the risk of GIC independently and jointly.
This large-scale prospective cohort study included 105,463 participants in UK Biobank who were aged 40–72 y and cancer-free at baseline. Dietary intake (Oxford WebQ) was used to calculate dietary pattern scores including dietary approach to stop hypertension (DASH) score and healthful plant-based diet index (hPDI). Genetic risk was quantified by a polygenic risk score (PRS) comprising 129 known GIC-associated loci. Cox proportional hazards regression was performed to estimate the associations of dietary patterns and PRS with GIC incidence after adjusting for potential confounders.
Over a median follow-up of 11.70 y, 1,661 participants were diagnosed with GIC. DASH and hPDI were associated with 20% and 36% reductions, respectively, in GIC risk. Low PRS was associated with a 30 % decrease in GIC risk (HR: 0.70; 95% CI: 0.62, 0.79). Participants with healthy dietary scores at high-genetic risk had a lower GIC risk with HR of 0.77 (95% CI: 0.60, 0.98) for DASH and 0.66 (95% CI: 0.52, 0.84) for hPDI than those with unhealthy dietary score. Participants with both high-dietary score and low-genetic risk showed the lowest risk of GIC, with HR of 0.58 (95% CI: 0.45, 0.75) for DASH and 0.45 (95% CI: 0.34, 0.58) for hPDI.
Adherence to DASH and hPDI were associated with a lower risk of some gastrointestinal cancers, and these 2 dietary patterns may partly compensate for genetic predispositions to cancer. Our results advance the development of precision medicine strategies that consider both dietary patterns and genetics to improve gastrointestinal health.

View all citing articles on Scopus

: Conflicts of interest The authors disclose no conflicts.

: Funding This work was supported by the US National Institutes of Health (NIH) (grants NIDDK R01 DK105118, R01DK114126) and the UIC Cancer Center (support to Jun Sun); the American Cancer Society (grant number MRSG-17-220-01 – NEC to Mingyang Song); and NIH grants (K99 CA215314 and R00 CA215314 to Mingyang Song; K24 DK098311, R01 CA137178, R01 CA202704, R01 CA176726 to Andrew T. Chan). Andrew T. Chan is a Stuart and Suzanne Steele MGH Research Scholar.

View full text

ReviewInfluence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer

Section snippets

Intestinal Dysbiosis in Patients With Colorectal Cancer

Environmental Factors

Mechanisms

Screening

Therapy

Future Directions

Clin Gastroenterol Hepatol

Cancer Cell

Genes Dis

Gastroenterology

Gastroenterology

Genes Dis

Cell

Cell Metab

Cancer statistics, 2019

CA Cancer J Clin

Colorectal cancer statistics, 2017

CA Cancer J Clin

Nutrients, foods, and colorectal cancer prevention

Gastroenterology

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States

CA Cancer J Clin

Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location

Clin Transl Gastroenterol

International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis

Gut

Microbiota: a key orchestrator of cancer therapy

Nat Rev Cancer

The role of microbiota in the development of colorectal cancer

Int J Cancer

The gastrointestinal microbiota and colorectal cancer

Am J Physiol Gastrointest Liver Physiol

Novel insights into microbiome in colitis and colorectal cancer

Curr Opin Gastroenterol

A new genomic blueprint of the human gut microbiota

Nature

Human gut microbiome and risk for colorectal cancer

J Natl Cancer Inst

Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation

Nat Med

Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors

MBio

Gut microbiome development along the colorectal adenoma-carcinoma sequence

Nat Commun

Gut mucosal microbiome across stages of colorectal carcinogenesis

Nat Commun

Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer

Nat Med

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma

Genome Res

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

Genome Res

Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome

Eur J Clin Microbiol Infect Dis

Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway

Int J Cancer

Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients

World J Gastroenterol

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis

Gut

Fusobacterium in colonic flora and molecular features of colorectal carcinoma

Cancer Res

Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy

Cell

Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer

World J Gastroenterol

Fusobacterium nucleatum and T cells in colorectal carcinoma

JAMA Oncol

Sessile serrated polyps and colon cancer prevention

Cancer Prev Res (Phila)

Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer

Sci Rep

The consensus molecular subtypes of colorectal cancer

Nat Med

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

Science

The human gut microbiome as a screening tool for colorectal cancer

Cancer Prev Res (Phila)

Review
Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer